NetScientific plc

NSCI.L · London Stock Exchange · GBp

53,12GBp

−0,38 (−0,71 %)Stand 25. Sept., 13:07

Vortag 53,50

Kennzahlen

Eröffnung
53,15
Vortag
53,50
Tagesspanne
53,12 – 53,15
52 Wochen
48,00 – 80,50
Volumen
4644
Ø Volumen
18.498
Börsenwert
12,72 Mio. p
KGV
–
Gewinn je Aktie (TTM)
–
Dividendenrendite
–
Beta
1,7
Nächste Zahlen
–

Finanzen

Gerade nicht verfügbar.

Bewertung

Gerade nicht verfügbar.

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

Okt. 2023Sept. 2022Sept. 2021
Gewinn je Aktie · Erwartet–––
Gewinn je Aktie · Tatsächlich-0,06-0,07-0,08
Abweichung–––
Umsatz · Tatsächlich770.000391.000407.000

Dividenden und Splits

Keine Dividenden gezahlt.

Aktiensplits

  • 25. Aug. 20201:10

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

–

Vergleichbare Unternehmen

Über das Unternehmen

NetScientific plc operates as a venture capital entity, strategically deploying capital into companies at their initial, emergent, and growth stages. Its primary investment interests lie in sustainability, advanced technology, and groundbreaking biomedical and healthcare innovations. Within the healthcare sphere, the firm specifically targets digital health, diagnostics, and therapeutics, with a particular emphasis on ventures that enhance the well-being and health outcomes for individuals suffering from chronic diseases. Its digital health focus encompasses data analytics, wearable technologies, and various medical devices. Geographically, NetScientific actively seeks opportunities in established European markets and across the United States. While typical investments may reach £15 million (approximately $20.32 million), the firm is prepared to commit larger sums. A core strategy is to secure a controlling interest in its principal subsidiary companies, with funding predominantly sourced from its own balance sheet. NetScientific plc was established in 2008 and is headquartered in London, United Kingdom.

Führung

  • Ilian Petkov IlievChief Executive Officer & Executive Director
  • Edward Benjamin Peter HooperGeneral Counsel & Executive Director
  • Christopher NiehausAdviser
  • Ian CookeVenture Partner of Sustainability
  • Anete MerheleMarketing Manager
  • Hannah JarvisFinancial Controller
CEO
Ilian Petkov Iliev
Mitarbeitende
29
Hauptsitz
London, GB
Sektor
Healthcare
Branche
Biotechnology
Börsengang
16. Sept. 2013

Nachrichten

Gerade keine Nachrichten zu diesem Unternehmen.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.